The double-edged sword of innovation Read More

Investors are plowing big bucks into DNA engineering. Here’s the best-positioned play on this fast-growing biotech arena. Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More